BARTALUCCI, NICCOLO'
BARTALUCCI, NICCOLO'
Medicina Sperimentale e Clinica
A blood drop through the pore: nanopore sequencing in hematology
2021 Bartalucci N.; Romagnoli S.; Vannucchi A.M.
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
2021 Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M.
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
2022 Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation
2017 Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
2019 Salati S.; Genovese E.; Carretta C.; Zini R.; Bartalucci N.; Prudente Z.; Pennucci V.; Ruberti S.; Rossi C.; Rontauroli S.; Enzo E.; Calabresi L.; Balliu M.; Mannarelli C.; Bianchi E.; Guglielmelli P.; Tagliafico E.; Vannucchi A.M.; Manfredini R.
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value
2014 Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P.
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
2014 Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
2014 Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
2020 Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M.
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
2013 Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM
Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice
2022 Maria Elena Melica, Giulia Antonelli, Roberto Semeraro, Maria Lucia Angelotti, Gianmarco Lugli, Samuela Landini, Fiammetta Ravaglia, Gilda La Regina, Carolina Conte, Letizia De Chiara, Anna Julie Peired, Benedetta Mazzinghi, Marta Donati, Alice Molli, Stefanie Steiger, Alberto Magi, Niccolò Bartalucci, Valentina Raglianti,, Francesco Guzzi, Laura Maggi, Francesco Annunziato, Alexa Burger, Elena Lazzeri, Hans-Joachim Anders, Laura Lasagni, Paola Romagnani
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
2015 Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
2018 Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M; Lasho, Terra L; Hanson, Curtis A; Ketterling, Rhett P; Begna, Kebede H; Naseema Gangat, null; Pardanani, Animesh; Vannucchi, Alessandro M
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
2010 Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
2023 Bianchi, Elisa; Rontauroli, Sebastiano; Tavernari, Lara; Mirabile, Margherita; Pedrazzi, Francesca; Genovese, Elena; Sartini, Stefano; Dall'Ora, Massimiliano; Grisendi, Giulia; Fabbiani, Luca; Maccaferri, Monica; Carretta, Chiara; Parenti, Sandra; Fantini, Sebastian; Bartalucci, Niccolò; Calabresi, Laura; Balliu, Manjola; Guglielmelli, Paola; Potenza, Leonardo; Tagliafico, Enrico; Losi, Lorena; Dominici, Massimo; Luppi, Mario; Vannucchi, Alessandro Maria; Manfredini, Rossella
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
2017 Ruberti, S; Bianchi, E; Guglielmelli, P; Rontauroli, S; Barbieri, G; Tavernari, L; Fanelli, T; Norfo, R; Pennucci, V; G. Corbizi, Fattori; Mannarelli, C; Bartalucci, N; Mora, B; Elli, L; Avanzini, M. A; Rossi, C; Salmoiraghi, S; Zini, R; Salati, S; Prudente, Z; Rosti, V; Passamonti, F; Rambaldi, A; Ferrari, S; Tagliafico, E; Vannucchi, A. M; Manfredini, R.
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)
2019 Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD
JAK PI3K/mTOR COMBINATION THERAPY
2013 Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci
Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing
2019 Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
2022 Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A blood drop through the pore: nanopore sequencing in hematology | 2021 | Bartalucci N.; Romagnoli S.; Vannucchi A.M. | |
| Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs | 2021 | Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M. | |
| ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera | 2022 | Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M | |
| Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation | 2017 | Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella | |
| Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants | 2019 | Salati S.; Genovese E.; Carretta C.; Zini R.; Bartalucci N.; Prudente Z.; Pennucci V.; Ruberti S.; Rossi C.; Rontauroli S.; Enzo E.; Calabresi L.; Balliu M.; Mannarelli C.; Bianchi E.; Guglielmelli P.; Tagliafico E.; Vannucchi A.M.; Manfredini R. | |
| Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value | 2014 | Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P. | |
| Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. | 2014 | Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P | |
| Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. | 2014 | Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM | |
| Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms | 2020 | Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. | |
| Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. | 2013 | Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM | |
| Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice | 2022 | Maria Elena Melica, Giulia Antonelli, Roberto Semeraro, Maria Lucia Angelotti, Gianmarco Lugli, Samuela Landini, Fiammetta Ravaglia, Gilda La Regina, Carolina Conte, Letizia De Chiara, Anna Julie Peired, Benedetta Mazzinghi, Marta Donati, Alice Molli, Stefanie Steiger, Alberto Magi, Niccolò Bartalucci, Valentina Raglianti,, Francesco Guzzi, Laura Maggi, Francesco Annunziato, Alexa Burger, Elena Lazzeri, Hans-Joachim Anders, Laura Lasagni, Paola Romagnani | |
| Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial | 2015 | Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M | |
| GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis | 2018 | Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M; Lasho, Terra L; Hanson, Curtis A; Ketterling, Rhett P; Begna, Kebede H; Naseema Gangat, null; Pardanani, Animesh; Vannucchi, Alessandro M | |
| Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. | 2010 | Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A | |
| Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model | 2023 | Bianchi, Elisa; Rontauroli, Sebastiano; Tavernari, Lara; Mirabile, Margherita; Pedrazzi, Francesca; Genovese, Elena; Sartini, Stefano; Dall'Ora, Massimiliano; Grisendi, Giulia; Fabbiani, Luca; Maccaferri, Monica; Carretta, Chiara; Parenti, Sandra; Fantini, Sebastian; Bartalucci, Niccolò; Calabresi, Laura; Balliu, Manjola; Guglielmelli, Paola; Potenza, Leonardo; Tagliafico, Enrico; Losi, Lorena; Dominici, Massimo; Luppi, Mario; Vannucchi, Alessandro Maria; Manfredini, Rossella | |
| Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients | 2017 | Ruberti, S; Bianchi, E; Guglielmelli, P; Rontauroli, S; Barbieri, G; Tavernari, L; Fanelli, T; Norfo, R; Pennucci, V; G. Corbizi, Fattori; Mannarelli, C; Bartalucci, N; Mora, B; Elli, L; Avanzini, M. A; Rossi, C; Salmoiraghi, S; Zini, R; Salati, S; Prudente, Z; Rosti, V; Passamonti, F; Rambaldi, A; Ferrari, S; Tagliafico, E; Vannucchi, A. M; Manfredini, R. | |
| Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) | 2019 | Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD | |
| JAK PI3K/mTOR COMBINATION THERAPY | 2013 | Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci | |
| Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing | 2019 | Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M | |
| Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis | 2022 | Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM |